Sixteen leprosy cases detected in Kelantan since 2023

GUA MUSANG: Sixteen leprosy cases have been detected in Kelantan from 2023 up to the middle of this year.
State Health Director Datuk Dr Zaini Hussin said three cases were recorded this year, seven in 2023 and six throughout 2024.
'In 2023, there were seven cases, five were Multibacillary (MB) type and two were Paucibacillary (PB). For 2024, six cases were recorded, all of which were of the MB type.
'The Health Ministry (MoH) has implemented preventive treatment for leprosy through the administration of Single Dose Rifampicin (SDR) to individuals who had close contact with patients, as a step to reduce the risk of infection,' he told reporters after opening the 2025 Kelantan-Level World Leprosy Day celebration at Kampung Pasir Linggi, Pos Lebir, here today.
He said all patients who have completed treatment must undergo extended monitoring at treatment centres, five years for PB cases and ten years for MB cases.
'The treatment duration for PB patients is six months, while for MB cases it is 12 months. The MoH carries out continuous monitoring, especially in areas identified as high-risk,' he said.
Dr Zaini said leprosy does not have distinct symptoms and is often confused with other skin conditions, such as 'panau' (tinea versicolor), a superficial fungal skin infection that causes discolored patches on the skin.
'There may be whitish patches on the skin, but a key difference is the loss of sensation in the affected area due to nerve damage.
'Therefore, early screening and collecting skin smears are essential for laboratory analysis,' he said.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Rakyat Post

17 hours ago

• Rakyat Post

Malaysia Records First COVID-19 Death In 2025

Subscribe to our FREE Malaysia has recorded its first COVID-19-related death of 2025, according to a statement released by the Ministry of Health (MoH) on 19 June. The fatality occurred during Epidemiological Week 24 (8–15 June). The individual, who had serious pre-existing health conditions such as heart disease and diabetes, had not received the second booster dose of the COVID-19 vaccine. MoH noted that this was the first COVID-19 death since 26 May 2024, and a significant drop compared to the 57 COVID-related deaths reported in 2024. COVID-19 Cases on the Rise, But Situation Under Control As of Week 24, Malaysia has reported 21,738 cumulative COVID-19 cases in 2025, with the weekly average hovering around 900 cases. However, MoH did flag a 68% week-on-week spike, with 3,379 cases reported in Week 24 compared to 2,011 the previous week. Despite the increase, the ministry assured that the national COVID-19 situation remains stable and below the national alert threshold. In terms of severe cases, six patients were admitted to the ICU, all with underlying health issues. All have since been discharged from intensive care; four have returned home, while two remain in regular hospital wards for follow-up treatment. New Variant on the Radar: NB.1.8.1 or 'Nimbus' The World Health Organisation (WHO) is closely monitoring the spread of NB.1.8.1, a Photo: Freepik WHO has classified Nimbus as a Variant Under Monitoring (VUM) due to its rapid transmission and potential health risks. Nimbus spreads faster than previous variants. Common symptoms include: razor-blade-like sore throat, fatigue, mild cough, fever, muscle aches and nasal congestion. What You Can Do Health experts continue to urge the public to take precautions, especially as new variants emerge. Wear a high-quality mask in crowded indoor spaces, improve indoor ventilation: open windows, use fans or air purifiers, get tested if you're feeling unwell or exposed to COVID-19, and stay home when sick to reduce the risk of transmission. Photo: Malay Mail While Malaysia's current COVID-19 situation remains under control, this latest death and the emergence of new variants serve as reminders that vigilance and public health measures remain crucial. Share your thoughts with us via TRP's . Get more stories like this to your inbox by signing up for our newsletter.

Barnama

19 hours ago

• Barnama

Kelantan Records Decline In Dengue Cases, Wolbachia Mosquito Release Shows Results

KOTA BHARU, June 20 (Bernama) -- The number of dengue fever cases in Kelantan dropped by 12.5 percent, with 875 cases recorded in the first half of this year compared to 1,000 cases during the same period last year, said State Health director Datuk Dr Zaini Hussin. However, he noted that the number of dengue outbreaks rose to 66 from 50 in the same period, although no fatalities were reported. 'This year, there have been no dengue hotspot localities in Kelantan. The current trend remains low, with 17 cases reported in epidemiological week 24. 'Kelantan currently ranks ninth among Malaysian states with the highest number of dengue cases,' he told Bernama at the Gotong-Royong Mega Perangi Aedes 1.0 launch and release of Wolbachia-infected Aedes mosquitoes, officiated by state executive councillor for Local Government, Housing, Health and Environment, Hilmi Abdullah. Dr Zaini also reported that 180,414 premises have been inspected for Aedes mosquito breeding grounds in Kelantan as of mid-June this year, resulting in 501 compounds issued, amounting to RM250,000. He said a total of 73,900 Wolbachia-infected Aedes mosquitoes have been released in Pondok Terusan, Pasir Tumboh, and Kubur Maras, Kota Bharu in 2021, and in Bandar Baru Kubang Kerian today. He noted that no dengue cases have been reported in Pondok Terusan since the release, compared to 134 cases over the previous five years. 'In Kubur Maras, only two dengue cases have been recorded, one each in 2023 and 2024, compared to 81 cases in the five years before 2021,' he said. Dr Zaini added that the Ministry of Health (MOH) has spent an estimated RM705,500 over the past four years on dengue control efforts in Pondok Terusan and Kubur Maras.

The Star

a day ago

• The Star

S'poreans can test for genetic condition causing high cholesterol levels under new programme

The new genetic testing programme for familial hypercholesterolaemia comes amid broader efforts to enhance preventive care in Singapore. - AFP SINGAPORE: Eligible Singapore residents will be able to screen for a genetic condition which causes high cholesterol levels at a subsidised rate as part of a nationwide programme launching on June 30. In a statement on June 19, the Ministry of Health (MOH) said that the new genetic testing programme for familial hypercholesterolaemia (FH) comes amid broader efforts to enhance preventive care in Singapore. The initiative aims to identify individuals with FH early and reduce the risk of premature heart disease with timely interventions. FH is a hereditary condition that impacts the body's ability to process cholesterol, affecting roughly 20,000 people in Singapore. People with the condition are up to 20 times more likely to experience heart attacks at a younger age compared with the general population. In a Facebook post on June 19, Health Minister Ong Ye Kung said that the Government is looking to expand preventive care based on genetic testing to more diseases beyond FH. 'It is part of our longer term effort to develop predictive preventive care under Healthier SG,' he said. As part of this effort, the ministry aims to open three genomic assessment centres (GACs) to ensure effective, efficient and sustainable delivery of genetic testing services within each healthcare cluster. Genetics testing for FH at these centres will be subsidised for eligible Singapore citizens and permanent residents (PRs). They can also tap on MediSave to offset the cost. Those referred to GACs will undergo: Pre-test genetic counselling to understand potential outcomes and benefits before consenting to the test Blood drawing and the genetic test Post-test genetic counselling, to understand the implications of the results The first GAC will be operated by SingHealth and located at the National Heart Centre. It will start accepting referrals from June 30. This centre will serve all Singapore residents until additional centres open. GACs operated by National Healthcare Group and National University Health System will subsequently open to cater to residents' needs. Immediate family members of those found with the condition are at risk and encouraged to undergo genetic testing, MOH said. Known as cascade screening, this process enables early detection of FH within families. It also allows for more timely intervention and treatment, such as advising them to adopt healthier lifestyles or starting on cholesterol-lowering therapies. Under the programme, Singapore citizens and PRs with abnormally high cholesterol levels may be referred by their doctors for genetic testing. Eligible Singaporeans and PRs can receive subsidies of up to 70 per cent for the costs, which include the genetic tests, pre-test and post-test counselling, and phlebotomy services. Seniors from the Pioneer Generation and Merdeka Generation are also eligible for additional subsidies. After subsidies, referred patients can expect to pay between US$117 (US$91.06) and US$575. Those eligible for cascade screening can expect to pay between US$53 and US$253 after subsidies. The MediSave500 and MediSave700 scheme can be used to further offset the cost of the genetic test after subsidies. Patients who are 60 years old and above may also use Flexi-MediSave to further defray out-of-pocket costs. Under a moratorium on genetic testing and insurance introduced by MOH and the Life Insurance Association Singapore (LIA) in 2021, life insurers here are banned from using predictive genetic test results in assessing the outcome of insurance applications, unless certain criteria are satisfied. Insurers are also not allowed to use genetic test results from biomedical research or direct-to-consumer genetic test results. MOH said it has worked with the LIA to amend the moratorium to disallow life insurers in Singapore to use the results of all genetic tests conducted under the national FH genetic testing programme. They may, however, continue to request for individuals to disclose existing diagnosed conditions and family history. The amended moratorium will take effect from June 30. - The Straits Times/ANN